<DOC>
	<DOCNO>NCT00532337</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety ONO-5334 postmenopausal woman osteopenia osteoporosis .</brief_summary>
	<brief_title>Controlled Study ONO-5334 Postmenopausal Women With Osteopenia Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<criteria>1 . Osteoporosis define value DXA BMD 2.5 SD young adult mean ( Tscore , ≤2.5 ) lumbar spine ( L1 L4 ) total hip , OR Osteoporosis define value DXA BMD 1 SD young adult mean , le 2.5 SD value ( Tscore &lt; 1 &gt; 2.5 ) lumbar spine ( L1 L4 ) total hip . 1 . Patients value DXA BMD 3.5 SD young adult mean , ( Tscore &lt; 3.5 ) lumbar spine ( L1 L4 ) total hip . 2 . Osteoporosis patient ( Tscore ≤2.5 ) vertebral fragility fracture T4 L4 inclusive . 3 . Osteopenia patient ( Tscore &lt; 1 &gt; 2.5 ) vertebral fragility fracture T4 L4 inclusive , OR Osteopenia patient ( Tscore &lt; 1 &gt; 2.5 ) two vertebral fragility fracture T4 L4 inclusive . 4 . Patients abnormalities lumbar spine femoral neck internal organ around preclude assessment BMD . 5 . Patients secondary cause osteoporosis disorder bone mineral metabolism . 6 . Other exclusion criterion specify study protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>ONO-5334</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>osteopenia</keyword>
</DOC>